Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PREPARE-iVAC
NL-OMON58628Phase 4Completed
- Sponsor
- University Medical Center Groningen
- Start
- Aug 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of everolimus in immunocompromise (2 arms), sponsored by University Medical Center Groningen. Started Aug 2023; status: completed.
02
Drugs
everolimus
03
Conditions
immunocompromise
Beyond the preview
Go deeper on NL-OMON58628.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON58628.